We chose the fluoroquinolone antibiotic ciprofloxacin because it is frequently used to treat early P. aeruginosa infections in CF patients and is bactericidal toward stationary phase P. aeruginosa as it targets DNA gyrase [25,26]. The gene discussed is TOP2A; the disease is cystic fibrosis.